Course Description
Schizophrenia is often a lifelong condition that begins in early adulthood and is associated with significant adverse outcomes. Although there is no cure for schizophrenia, numerous antipsychotics are available for initial and maintenance therapy, with the goal of controlling symptoms. However, these medications work mainly by modulating dopamine and are poorly suited to address negative symptoms and cognitive dysfunction related to schizophrenia. For many patients, this results in debilitating residual symptoms, difficulties with adherence, and occasional medication-related adverse effects. In addition, there is a subset of patients who are considered to have ultra-treatment-resistant schizophrenia and have minimal or no response to clozapine, the most effective antipsychotic. To address these gaps in therapy, new research combined with an increased understanding of the etiology and pathophysiology of schizophrenia is leading to the development of novel agents that focus on negative symptoms, cognitive dysfunction, adherence, antipsychotic adverse effect profiles, and treatment-resistant schizophrenia. A number of medications currently under study have novel mechanisms of action. These new treatment strategies include modulators of serotonin and glutamate, agonists of TAAR-1, antagonists of σ-2, and muscarinic receptor agonists. There are also new dosage forms that aid in adherence. With the increasing number of treatment modalities on the horizon, this session is designed to provide evidence around these novel treatments including how they work and their potential role in the treatment of schizophrenia.
Learning Objectives
- Evaluate the efficacy and/or safety of emerging non-dopaminergic treatment modalities for schizophrenia.
- Determine which patients with schizophrenia are the best candidates for treatment with non-dopaminergic medications based on their symptoms, comorbidities, and/or medication histories.
- Formulate a treatment plan for a patient with schizophrenia using new and emerging non-dopaminergic medications.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Austin R.Campbell, PharmD, BCPP
Clinical Assistant Professor
UMKC School of Pharmacy at MU
Columbia, MO
Dr. Austin Campbell Pharm.D., BCPP, is a Clinical Assistant Professor with University of Missouri – Kansas City School of Pharmacy at MU in Columbia, Missouri. Additionally, he is an adjunct assistant professor with the University of Missouri Medical School. Currently he practices as a psychiatric ambulatory care pharmacist in the internal medicine and geriatric clinics.
Dr. Campbell graduated from the UMKC School of Pharmacy in 2008. He went on to completed a first year postgraduate residency at the Kansas City VA Medical Center and a second year specialty residency in psychiatry at the Center for Behavioral Medicine in Kansas City before obtaining his board certification in psychiatric pharmacy (BCPP). Prior to his current appointment, Dr. Campbell served as the acute inpatient psychiatric pharmacist for adults and pediatrics at University of Missouri Health Care in Columbia, Missouri for more than 11 years.
As an avid educator, Dr. Campbell has received multiple awards for his service to the community and commitment to training students, residents, and fellows. He is recognized throughout the state of Missouri for his outreach and education efforts with the National Alliance on Mental Illness (NAMI), the Department of Mental Health, Missouri Telehealth Network, and the Missouri Children’s Health Integration Learning and Development (MO CHILD) Center for Excellence. Since 2016 he has been an active member of Project ECHO (Extension for Community Healthcare Outcomes) and has helped in the creation and launch of two separate ECHOs. Dr. Campbell is an active member of the College of Psychiatric and Neurologic Pharmacists (CPNP) serving as a member of multiple committees and editorial boards and is the current programing chair for the 2022, 25th Annual Meeting.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 04/24/2022
ACPE Contact Hours: 1
ACPE Number: 0284-0000-22-032-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2022 Program Committee and Recertification Editorial Board
|
Elayne D. Ansara, PharmD, BCPP, BCPS Clinical Pharmacy Specialist Veteran Health Indiana Indianapolis, IN No Relevant Financial Relationships to Disclose |
|
Sarah L. Benner, PharmD, BCPS, BCPP Clinical Pharmacy Coordinator and Psychiatric Clinical Pharmacist Peninsula Regional Medical Center Salisbury, MD No Relevant Financial Relationships to Disclose |
 Jolene R. Bostwick, PharmD, BCPP, BCPSProgram Administrative Chair Assistant Dean for Co-Curriculum and Professional Development & Clinical Professor University of Michigan College of Pharmacy Ann Arbor, MI No Relevant Financial Relationships to Disclose |
|
Bridget Bradley, PharmD, BCPP |
|
|
|
Chelsea N. Carr, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland School of Pharmacy Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Dana Chiulli, PharmD, BCPP Clinical Pharmacist - Mental Health VISN 06 Mental Health Clinical Resource Hub Savannah, GA No Relevant Financial Relationships to Disclose |
|
Andria F. Church, PharmD, BCPP, BCPS Assistant Professor Palm Beach Atlantic University West Palm Beach, FL No Relevant Financial Relationships to Disclose |
|
Jordan Cooler, PharmD, BCPP Clinical Assistant Professor University of South Carolina College of Pharmacy Columbia, SC No Relevant Financial Relationships to Disclose |
 Beth DeJongh, PharmD, BCPP, BCPS
Recertification Editorial Board Chair
PharmacistConcordia University Wisconsin Mequon, WI No Relevant Financial Relationships to Disclose |
|
Bennett J. Doughty, PharmD, BCPP, BCPS |
|
Amber R. Douglass, PharmD, BCPS, BCPP Clinical Pharmacy Specialist - Mental Health VISN 1 Clinical Resource Hub - VA Connecticut Healthcare System West Haven, CT No Relevant Financial Relationships to Disclose |
|
Traci M. Dutton, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health VA Tennessee Valley Healthcare System Murfreesboro, TN No Relevant Financial Relationships to Disclose |
Megan J. Ehret, PharmD, BCPP, MS |
|
Kristen N. Gardner, PharmD, BCPP |
|
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Weitzman Institute Project ECHO Faculty |
|
Stacy L. Gould, PharmD, BCGP, BCPP |
|
Rebecca Graham, PharmD, BCPP Clinical Pharmacy Specialist - Mental Health Orlando VA Healthcare System Orlando, FL No Relevant Financial Relationships to Disclose |
|
Nicole Hahn, PharmD, BCACP Clinical Pharmacy Specialist - Neurology Kaiser Permanente Denver, CO No Relevant Financial Relationships to Disclose |
|
Abigail Hampton, PharmD, BCPP Psychiatric Clinical Pharmacist - Ambulatory University of Kansas Health System Kansas City, KS No Relevant Financial Relationships to Disclose |
|
Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
|
Archana R. Jhawar, PharmD, BCPP Clinical Pharmacist Jesse Brown VAMC/ UIC College of Pharmacy Chicago, IL No Relevant Financial Relationships to Disclose |
|
Kayla D. Johnson, PharmD, BCPP, BCPS Vanderbilt University Medical Center Thompsons Station, TN No Relevant Financial Relationships to Disclose |
|
Dongmi Kim, PharmD, BCPP, BCPS Assistant Clinical Professor Fairleigh Dickinson University School of Pharmacy Florham Park, NJ No Relevant Financial Relationships to Disclose |
|
Erin D. Knox, PharmD, BCPP Director of Experiential Education UCI School of Pharmacy & Pharmaceutical Sciences Irvine, CA Non-Financial Interests: Santa Ana Community College, Pharmacy Technology Program, Advisory Committee |
|
Amber R. Lemons, PharmD, BCPP Behavioral Health Pharmacist Denver Health Medical Center Denver, CO No Relevant Financial Relationships to Disclose |
|
Linda D. Logan, PharmD, BCACP, BCPP, BCPS Public Service Associate University of Georgia Athens, GA Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant |
|
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP Dean and Professor University of Montana, Skaggs School of Pharmacy Missoula, MT External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Editorial Board member: Continuum: Lifelong Learning in Neuroilogy, consultant for Lexicomp as a clinical specialist in neurology and psychiatry |
|
Monica Mathys, PharmD, BCGP, BCPP Associate Professor Texas Tech University School of Pharmacy Dallas, TX Non-Financial Interests: CPNP Foundation Board member |
|
Melissa Mitchell, PharmD, BCGP, BCPP, BCPS Senior Clinical Pharmacist RUHS MC Moreno Valley , CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Neurocrine Speakers Bureau - Ingrezza, Janssen Speakers Bureau - Spravato, Otsuka - PsychU.org Speaker |
|
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL No Relevant Financial Relationships to Disclose |
|
Jessica L. Mulhollan, PharmD, BCPP Clinical Pharmacy Specialist, Substance Use Disorders Louis Stokes Cleveland VA Medical Center Cleveland, OH No Relevant Financial Relationships to Disclose |
|
Kristen Neumeister, PharmD, BCPP Clinical Pharmacist- Mental Health John Peter Smith Hospital Fort Worth, TX No Relevant Financial Relationships to Disclose |
|
Megan O'Connell, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland - Clifton T. Perkins Hospital Baltimore, MD No Relevant Financial Relationships to Disclose |
|
Melissa C. Palmer, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health Alaska VA Healthcare System Anchorage, AK No Relevant Financial Relationships to Disclose |
|
Jake R. Peters, PharmD, BCPP, BCPS Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry Butler University College of Pharmacy/Indiana University Health Indianapolis, IN No Relevant Financial Relationships to Disclose |
|
Lindsey Peters, PharmD, BCPS Associate Professor of Pharmacy Practice Ohio Northern University Ada, OH No Relevant Financial Relationships to Disclose |
|
Sarah J. Popish, PharmD, BCPP Academic Educator Department of Veterans Affairs Vallejo, CA No Relevant Financial Relationships to Disclose |
|
Kristina Reinstatler, PharmD, BCPP, MBA Clinical Pharmacy Specialist UC Health University of Cincinnati Medical Center Cincinnati, OH Educational Grants, Research Grants or Contracts: HEALing Communities NIH grant- pharmacy lead Athens Cty, Ohio |
|
Michael D. Shuman, PharmD, BCPP Staff Pharmacist Central State Hospital Lousiville, KY No Relevant Financial Relationships to Disclose |
|
Taylor A. Thomas, PharmD, BCPP Clinical Pharmacy Specialist- Mental Health VA Northern Indiana Health Care System Fort Wayne, IN No Relevant Financial Relationships to Disclose |
|
Nina Vadiei, PharmD, BCPP Assistant Professor University of Arizona Colleges of Pharmacy and Medicine Tucson, AZ No Relevant Financial Relationships to Disclose |
|
Kara R. Wong, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health; PGY2 Psychiatric Pharmacy Residency Program Director Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Ulotaront (SEP-856), Xanomeline and Trospium, Pimavanserin, Roluperidone (MIN-101).
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.